Cargando…
De Novo and Relapsing Glomerulonephritis following SARS-CoV-2 mRNA Vaccination in Microscopic Polyangiitis
Vaccination against SARS-CoV-2 is the most important advance in the fight against the ongoing coronavirus pandemic. Recent case reports show that the SARS-CoV-2 vaccines can very rarely cause de novo or relapsing glomerular disease. Here, we report two female patients with microscopic polyangiitis,...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556126/ https://www.ncbi.nlm.nih.gov/pubmed/34254648 http://dx.doi.org/10.1155/2021/8400842 |
_version_ | 1784592120413159424 |
---|---|
author | Davidovic, Tamara Schimpf, Judith Sprenger-Mähr, Hannelore Abbassi-Nik, Armin Soleiman, Afschin Zitt, Emanuel Lhotta, Karl |
author_facet | Davidovic, Tamara Schimpf, Judith Sprenger-Mähr, Hannelore Abbassi-Nik, Armin Soleiman, Afschin Zitt, Emanuel Lhotta, Karl |
author_sort | Davidovic, Tamara |
collection | PubMed |
description | Vaccination against SARS-CoV-2 is the most important advance in the fight against the ongoing coronavirus pandemic. Recent case reports show that the SARS-CoV-2 vaccines can very rarely cause de novo or relapsing glomerular disease. Here, we report two female patients with microscopic polyangiitis, who developed severe glomerulonephritis after immunisation with the BNT162b2 mRNA vaccine. One patient with a possible ongoing but undiagnosed disease developed severe necrotising glomerulonephritis after the second vaccination. In the other patient with a long-lasting disease, rituximab maintenance therapy had been postponed because of the coronavirus pandemic. She noted macrohematuria immediately after the second vaccine dose and developed a severe renal relapse leading to end-stage kidney disease. We suggest that patients with ANCA-associated vasculitis be carefully monitored for disease activity immediately before and after receiving the SARS-CoV-2 vaccination, especially if maintenance therapy has been interrupted. Ultimately, mRNA vaccines should probably be avoided in these patients. |
format | Online Article Text |
id | pubmed-8556126 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-85561262021-10-30 De Novo and Relapsing Glomerulonephritis following SARS-CoV-2 mRNA Vaccination in Microscopic Polyangiitis Davidovic, Tamara Schimpf, Judith Sprenger-Mähr, Hannelore Abbassi-Nik, Armin Soleiman, Afschin Zitt, Emanuel Lhotta, Karl Case Rep Nephrol Case Report Vaccination against SARS-CoV-2 is the most important advance in the fight against the ongoing coronavirus pandemic. Recent case reports show that the SARS-CoV-2 vaccines can very rarely cause de novo or relapsing glomerular disease. Here, we report two female patients with microscopic polyangiitis, who developed severe glomerulonephritis after immunisation with the BNT162b2 mRNA vaccine. One patient with a possible ongoing but undiagnosed disease developed severe necrotising glomerulonephritis after the second vaccination. In the other patient with a long-lasting disease, rituximab maintenance therapy had been postponed because of the coronavirus pandemic. She noted macrohematuria immediately after the second vaccine dose and developed a severe renal relapse leading to end-stage kidney disease. We suggest that patients with ANCA-associated vasculitis be carefully monitored for disease activity immediately before and after receiving the SARS-CoV-2 vaccination, especially if maintenance therapy has been interrupted. Ultimately, mRNA vaccines should probably be avoided in these patients. Hindawi 2021-10-22 /pmc/articles/PMC8556126/ /pubmed/34254648 http://dx.doi.org/10.1155/2021/8400842 Text en Copyright © 2021 Tamara Davidovic et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Davidovic, Tamara Schimpf, Judith Sprenger-Mähr, Hannelore Abbassi-Nik, Armin Soleiman, Afschin Zitt, Emanuel Lhotta, Karl De Novo and Relapsing Glomerulonephritis following SARS-CoV-2 mRNA Vaccination in Microscopic Polyangiitis |
title | De Novo and Relapsing Glomerulonephritis following SARS-CoV-2 mRNA Vaccination in Microscopic Polyangiitis |
title_full | De Novo and Relapsing Glomerulonephritis following SARS-CoV-2 mRNA Vaccination in Microscopic Polyangiitis |
title_fullStr | De Novo and Relapsing Glomerulonephritis following SARS-CoV-2 mRNA Vaccination in Microscopic Polyangiitis |
title_full_unstemmed | De Novo and Relapsing Glomerulonephritis following SARS-CoV-2 mRNA Vaccination in Microscopic Polyangiitis |
title_short | De Novo and Relapsing Glomerulonephritis following SARS-CoV-2 mRNA Vaccination in Microscopic Polyangiitis |
title_sort | de novo and relapsing glomerulonephritis following sars-cov-2 mrna vaccination in microscopic polyangiitis |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556126/ https://www.ncbi.nlm.nih.gov/pubmed/34254648 http://dx.doi.org/10.1155/2021/8400842 |
work_keys_str_mv | AT davidovictamara denovoandrelapsingglomerulonephritisfollowingsarscov2mrnavaccinationinmicroscopicpolyangiitis AT schimpfjudith denovoandrelapsingglomerulonephritisfollowingsarscov2mrnavaccinationinmicroscopicpolyangiitis AT sprengermahrhannelore denovoandrelapsingglomerulonephritisfollowingsarscov2mrnavaccinationinmicroscopicpolyangiitis AT abbassinikarmin denovoandrelapsingglomerulonephritisfollowingsarscov2mrnavaccinationinmicroscopicpolyangiitis AT soleimanafschin denovoandrelapsingglomerulonephritisfollowingsarscov2mrnavaccinationinmicroscopicpolyangiitis AT zittemanuel denovoandrelapsingglomerulonephritisfollowingsarscov2mrnavaccinationinmicroscopicpolyangiitis AT lhottakarl denovoandrelapsingglomerulonephritisfollowingsarscov2mrnavaccinationinmicroscopicpolyangiitis |